RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that Ken Song, M.D., President and CEO of the Company, will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023.

J.P. Morgan Healthcare Conference

Date: Monday, January 9, 2023

Time: 2:00 p.m. - 2:25 p.m. PST

Location: The Westin St. Francis – Golden Gate Room

About RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.